RT Journal Article
SR Electronic
T1 Iron deficiency in Women of Childbearing Age with Self-reported Oral Iron Gastrointestinal Intolerance and Management with an oral Iron-Whey-Protein Formulation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.01.21262983
DO 10.1101/2021.09.01.21262983
A1 Gilmer, JGF
A1 Ryan, Fiona
A1 Seoighe, Anna
A1 Santos-Martinez, Maria Jose
A1 Ryan, Cristin
A1 Ledwidge, Mark
YR 2021
UL http://medrxiv.org/content/early/2021/09/05/2021.09.01.21262983.abstract
AB Background Intolerance to oral iron is thought to result in poor adherence and persistence of nutritional deficit amongst women of childbearing age, however few studies have evaluated oral iron intolerance, iron deficiency and anaemia in this setting. Iron-whey protein microspheres (IWP) could help.Methods We documented self-reported oral iron gastrointestinal intolerance, ferritin and haemoglobin levels in a screening study of women of childbearing age. Following a washout period of 16 days, we randomised 59 of these women with iron deficiency, stratified according to the presence of anaemia, to three doses of IWP: (14mg daily, 25mg daily and 50mg daily). We excluded those with established gastrointestinal disease, potential allergy to whey protein and severe anaemia. The primary endpoint was persistence and adherence (>80% based on pill-counts). Secondary endpoints included changes in self-reported oral iron gastrointestinal intolerance, gastro-intestinal symptom rating scale (GSRS), serum iron, serum ferritin, transferrin saturation and haemoglobin levels.Results A total of 128 (62.7%) of the participants had low iron stores (ferritin < 30 µg/L), 65 (31.9%) had moderate to severe iron deficiency (ferritin <12 µg/L) and 33 (16.2%) had iron deficiency anaemia. Amongst 59 women who participated in the prospective study, 48 (81.4%) were classified as adherent/persistent with therapy using IWP compared to 12 (20.3%) taking the prior oral iron p<0.0001. These patients also showed significantly fewer reports of gastrointestinal intolerance with IWP (0.59 ± 0.91) and lower GSRS scores (6.2 ± 7.5) compared to the previous oral iron product (3.98 ± 2.22, and 15.6 ± 9.7 respectively, both P<0.0001). There were no differences in adherence, self-reported adverse GI effects and GSRS between the dose groups during the study. Serum iron levels increased across the whole cohort from 11.3 ± 7.4 μmol/L to 20.5± 11.0 μmol/L (P<0.0001), transferrin saturation levels increased from 18.4 ± 13.3 % to 33.6 ± 17.6 % (P<0.0001) and median ferritin levels overall increased from 8.00 [IQR 6.00;13.0] to 15.5 [IQR 9.00;24.2] µg/L at 12 weeks (P=0.0002). Haemoglobin levels increased from 11.36 g/dL (95%CI 10.95 to 11.77) to 12.40 g/dL (95%CI 12.03 to 12.76, P=0.0007) in patients with anaemia and were normalised in most patients taking 50mg IWP daily.Conclusions Low iron, iron deficiency and anaemia are common in women of childbearing age with a history of intolerance to oral iron. Patients with low iron (ferritin < 30 µg/L) and moderate to severe iron deficiency (ferritin <12 µg/L) have similar impairment of energy. IWP can improve self-reported oral iron adherence and tolerability as well as iron stores, haemoglobin and tiredness in these women.Competing Interest StatementJohn Gilmer and Mark Ledwidge hold patents in relation to oral formulations of iron and Iron-Whey-Protein and are founder shareholders of Solvotrin Therapeutics, which is commercialising Active Iron.Clinical TrialClinicalTrials.gov Identifier: NCT04778072Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04778072?term=solvotrin&draw=2&rank=1 Funding StatementProf. Gilmer and Ledwidge reports board membership and shares in Solvotrin Therapeutics. They are named inventors on several patents relating to oral formulations of iron. Prof Ledwidge has also received honoraria and research grants from Novartis, A Menarini, Servier, Abbott Diagnostics, Genuity Science Ireland and Bayer.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Cork University Hospital Research Ethics CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesConsent has not been obtained for publication of patient level data.BMIBody mass indexBpmbeats per minuteCIConfidence intervalDBPDiastolic blood pressureGIGastrointestinalGSRSGastrointestinal Symptom Rating Scale gut symptoms scoreHbhaemoglobinHRHeart rateIQRInterquartile rangeIWPiron-whey-protein formulationOROdds RatioSBPSystolic blood pressureSDstandard deviationTSATtransferrin saturation